Sunday, December 21, 2014 9:18:55 AM
Additionally, watering down this security's inability thus far not to land a BP Lympro JV Agreement and generate sustainable revenue against countless other heavily diluted biotechs does not force me to rethink my position with regards to it, nor take my eyes off the prize. I am in AMBS now 26 months and I still believe - even though the pps needle has not done what the CEO himself has pontificated it may. Bottom line is - it still could run north quickly - even under a 5-fold increase in the float, a potential massive RS coming, and an addit. 1-Bil. AS increase overhang.
Additionally, I did not mention the words "from the start" - you did.
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM